China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Change in Accured Expenses came in at -$14258.0 in Q1 2026, up 81.91% YoY from -$7838.0 in Q1 2025, and down 103.29% on a QoQ basis from $432777.0 in Q4 2025.
China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Change in Accured Expenses data on file, last reported at -$14258.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 81.91% year-over-year to -$14258.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $530304.0 (down 24.28% YoY) and the FY2025 annual result came in at $465753.0, up 8.01% from the prior year.
- Change in Accured Expenses fell to -$14258.0 in Q1 2026, from $432777.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $804339.0 in Q4 2022 to a low of -$450887.0 in Q1 2023.
- A 5-year average of $107804.6 and a median of $25734.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 579.2% — and 2023, when it jumped 940.44%.
- Tracing CPHI's Change in Accured Expenses over 5 years: stood at $804339.0 in 2022, then sank by 47.67% to $420886.0 in 2023, then surged by 73.24% to $729131.0 in 2024, then plunged by 40.64% to $432777.0 in 2025, then sank by 103.29% to -$14258.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$14258.0 (Q1 2026), $432777.0 (Q4 2025), and -$68702.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | China Pharma Holdings | 42.55 Mn | 42.24 Mn | 83,566.00 | 191,211.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,258.00 |
| Mar 31, 2026 | -14,258.00 |
| Dec 31, 2025 | 432,777.00 |
| Dec 31, 2025 | 432,777.00 |
| Sep 30, 2025 | -68,702.00 |
| Sep 30, 2025 | -68,702.00 |
| Jun 30, 2025 | 180,487.00 |
| Jun 30, 2025 | 180,487.00 |
| Mar 31, 2025 | -78,809.00 |
| Mar 31, 2025 | -78,809.00 |
| Dec 31, 2024 | 729,131.00 |
| Dec 31, 2024 | 729,131.00 |
| Sep 30, 2024 | -56,482.00 |
| Sep 30, 2024 | -56,482.00 |
| Jun 30, 2024 | 106,548.00 |
| Jun 30, 2024 | 106,548.00 |
| Mar 31, 2024 | -347,982.00 |
| Mar 31, 2024 | -347,982.00 |
| Dec 31, 2023 | 420,886.00 |
| Dec 31, 2023 | 420,886.00 |